Nosopharm: an innovative platform for the discovery of novel antibiotics from the microbial biodiversity

Nosopharm is a young biotech company who develops a novel biotecnological platform for the optimal exploitation of the exceptional medicinal potential of the microbial biodiversity. This platform affords us to:

- Discover and develop novel antibacterial molecules to cure antibiotic-multiresistant nosocomial infections, especially respiratory infections due to Gram-negative pathogens (Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Stenotrophomonas maltophilia, …)
- Make partnerships with companies willing to profit from their microbial bioresources for medicinal purpose, or willing to discover and characterize bioactive natural molecules that have never been described.